SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that CEO and Co-founder Dr. Jurgi Camblong will present at the NVIDIA GTC in San Jose, California on March 17, 2025 at 101:00 a.m. PDT. The session titled “Interpret Health Data With AI to Change the Future of Medicine,” will be live and broadcast virtually. Interested parties can visit the GTC website and register for session S71671.

This session expands on a collaboration announced last year with SOPHiA GENETICS, Microsoft, and NVIDIA on a whole genome sequencing (WGS) analytical solution. 

The SOPHiA DDM™ Platform enables healthcare organizations to get actionable insights from their data. Hosted on Azure and powered by NVIDIA Parabricks, an accelerated genomics software suite, the SOPHIA DDM quickly processes whole genomes to help provide invaluable insights.  

Replays will be available on the NVIDIA GTC website after completion.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on LinkedIn.  

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Contact:
Kellen Sanger
[email protected]

Media Contact:
Kelly Katapodis
[email protected]